Trial reportDrug design, development and therapy2026
Single-Injection Liposomal Bupivacaine Adductor Canal Block for Pain Control and Recovery After Total Knee Arthroplasty: A Randomized Controlled Double‑Blinded Study.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The efficacy of the adductor canal block (ACB) in multimodal analgesia following total knee arthroplasty (TKA) remains controversial. This study investigates the effects of local anesthetics single-injection ACB with different analgesic durations on TKA patients. Methods: This randomized controlled double‑blinded trial enrolled 90 patients undergoing primary TKA. Participants were randomized to receive ACB with either liposomal bupivacaine (LB), ropivacaine (15 mL of 0.3%), or in the control group, with 30 patients in each group. The primary end points included the static and dynamic visual analog scale (VAS) scores at 24 hours postoperatively. The secondary end points examined the static and dynamic pain scores at 6,12,48, and 72 hours postoperatively; the knee range of motion (ROM); quadriceps muscle strength; duration to first ambulation; opioid consumption; and related adverse events. Results: Patients administered a LB single-injection ACB (LB-ACB) demonstrated significantly reduced VAS scores at static and dynamic phases at 24 hours, relative to the ropivacaine single-injection ACB (R-ACB) and control group patients. We recorded a median interquartile range [IQR] of 1 (0.0-2.0 [0-4]) vs. 3 (2.0-4.0 [0-5]) vs. 3 (2.0-4.0 [0-6]) for static pain scores and 2.5 (1.0-3.25 [0-5]) vs. 4 (4.0-5.0 [2-7]) vs. 5 (4.0-6.0 [3-7]) for dynamic pain scores ( Conclusion: Among patients undergoing TKA, LB single-injection ACB offers a significant analgesic advantage compared to ropivacaine, lasting up to 24 hours. After 48 hours, there is no difference in analgesic effects when compared to the control group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.